Kindeva Drug Delivery, a global leader in drug-device combination products, has announced that it has acquired Summit Biosciences Inc., an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva’s ability to serve biopharma customers across a wider range of complex drug-device combination products.
Latham & Watkins LLP represented the lenders in a financing to support the transaction with a team led by New York partners Stelios Saffos and Nicole Fanjul and Chicago counsel Shahid Jamil, with associate Sharon Yin. Advice was also provided on tax matters by New York partner Bora Bozkurt, with associates Farrah Yan and Michael Yu.
